Wedbush Reiterates Outperform Rating for Werewolf Therapeutics (NASDAQ:HOWL)

Werewolf Therapeutics (NASDAQ:HOWL)‘s stock had its “outperform” rating reiterated by Wedbush in a report issued on Monday, RTT News reports. They presently have a $9.00 target price on the stock. Wedbush’s price objective would indicate a potential upside of 57.34% from the stock’s current price.

HOWL has been the subject of several other reports. JMP Securities reiterated a “market outperform” rating and issued a $12.00 price objective on shares of Werewolf Therapeutics in a research report on Monday. HC Wainwright reissued a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Monday.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $5.72 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 7.14 and a current ratio of 7.14. The business’s 50 day moving average price is $6.18 and its 200 day moving average price is $4.70. The company has a market cap of $247.96 million, a price-to-earnings ratio of -5.25 and a beta of 0.71. Werewolf Therapeutics has a one year low of $1.57 and a one year high of $8.19.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.10. Werewolf Therapeutics had a negative net margin of 256.33% and a negative return on equity of 36.43%. The firm had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.75 million. On average, research analysts predict that Werewolf Therapeutics will post -1.38 EPS for the current year.

Institutional Trading of Werewolf Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. PFM Health Sciences LP grew its stake in shares of Werewolf Therapeutics by 35.6% in the fourth quarter. PFM Health Sciences LP now owns 3,468,177 shares of the company’s stock valued at $13,387,000 after buying an additional 909,895 shares in the last quarter. Denali Advisors LLC acquired a new position in Werewolf Therapeutics in the 1st quarter valued at about $172,000. Lighthouse Investment Partners LLC purchased a new stake in Werewolf Therapeutics during the fourth quarter worth about $87,000. Certuity LLC acquired a new stake in shares of Werewolf Therapeutics during the fourth quarter worth about $39,000. Finally, Financial Perspectives Inc boosted its stake in shares of Werewolf Therapeutics by 80.0% in the fourth quarter. Financial Perspectives Inc now owns 6,750 shares of the company’s stock valued at $26,000 after purchasing an additional 3,000 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.